+

WO2006033995A3 - Thiazolidin-4-ones having anti-hepatitis b activity - Google Patents

Thiazolidin-4-ones having anti-hepatitis b activity Download PDF

Info

Publication number
WO2006033995A3
WO2006033995A3 PCT/US2005/033038 US2005033038W WO2006033995A3 WO 2006033995 A3 WO2006033995 A3 WO 2006033995A3 US 2005033038 W US2005033038 W US 2005033038W WO 2006033995 A3 WO2006033995 A3 WO 2006033995A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
thiazolidin
ones
activity
preventing
Prior art date
Application number
PCT/US2005/033038
Other languages
French (fr)
Other versions
WO2006033995A2 (en
Inventor
Robert K Hamatake
Huanming Chen
Anneke Raney
Matthew J Allan
Stanley Lang
Original Assignee
Valeant Res And Dev
Robert K Hamatake
Huanming Chen
Anneke Raney
Matthew J Allan
Stanley Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Res And Dev, Robert K Hamatake, Huanming Chen, Anneke Raney, Matthew J Allan, Stanley Lang filed Critical Valeant Res And Dev
Publication of WO2006033995A2 publication Critical patent/WO2006033995A2/en
Publication of WO2006033995A3 publication Critical patent/WO2006033995A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compounds having the following general structure (I): wherein X is S, O, or N and X’ is N or C. The compounds are useful for preventing and treating hepatitis B virus (HBV) infections in mammals, and for preventing and treating diseases associated with HBV infection.
PCT/US2005/033038 2004-09-16 2005-09-16 Thiazolidin-4-ones having anti-hepatitis b activity WO2006033995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61049404P 2004-09-16 2004-09-16
US60/610,494 2004-09-16

Publications (2)

Publication Number Publication Date
WO2006033995A2 WO2006033995A2 (en) 2006-03-30
WO2006033995A3 true WO2006033995A3 (en) 2006-06-01

Family

ID=36090506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033038 WO2006033995A2 (en) 2004-09-16 2005-09-16 Thiazolidin-4-ones having anti-hepatitis b activity

Country Status (1)

Country Link
WO (1) WO2006033995A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081627B2 (en) 2014-03-07 2018-09-25 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130793B (en) * 2011-11-30 2016-09-21 中国人民解放军军事医学科学院毒物药物研究所 3-(1-Arylpiperidine-4-base)-2-aryl thiazole quinoline-4-ketone compounds, Preparation Method And The Use
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP6141402B2 (en) 2012-03-31 2017-06-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 4-methyl-dihydropyrimidine for the treatment and prevention of hepatitis B virus infection
AU2013311705A1 (en) 2012-09-10 2015-02-05 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
CN103664916B (en) * 2012-09-12 2016-08-24 中国科学院化学研究所 Conjugation small molecule material based on sub-two pyrroles of bithiophene and derivant thereof and preparation method and application
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
EP2970132B1 (en) 2013-03-14 2020-09-23 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9776972B2 (en) 2013-03-14 2017-10-03 Epizyme Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
EP2970220A2 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2997032B1 (en) 2013-05-17 2018-07-25 F.Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2979490C (en) 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2017136403A1 (en) * 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
MY198617A (en) 2016-03-07 2023-09-11 Enanta Pharm Inc Hepatitis b antiviral agents
JP6581745B2 (en) 2016-04-06 2019-09-25 シャンハイ ジモン バイオファーマ カンパニー リミテッドＳｈａｎｇｈａｉ Ｚｈｉｍｅｎｇ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Pyrazole-oxazolidinone compound of anti-hepatitis B virus
US10189846B2 (en) 2016-06-10 2019-01-29 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR112019004560A2 (en) 2016-09-13 2019-07-02 Hoffmann La Roche combination treatment with tlr7 agonist and a hbv capsid formation inhibitor
WO2019046271A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AR115131A1 (en) 2017-11-02 2020-12-02 Aicuris Gmbh & Co Kg HIGHLY ACTIVE INDOLO-2-CARBOXAMIDES REPLACED WITH PYRAZOLO-PYRIMIDINE ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
GEP20227373B (en) 2017-11-02 2022-04-25 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TW201936192A (en) 2017-12-06 2019-09-16 美商因那塔製藥公司 Hepatitis B antiviral agents
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
UY38439A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NOVELTY UREA 6,7-DIHYDRO-4H-PYRAZOLE [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR117189A1 (en) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg DERIVATIVES OF 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
SG11202104132WA (en) 2018-11-02 2021-05-28 Aicuris Gmbh & Co Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
UY38437A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
AR116948A1 (en) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
IL283190B1 (en) 2018-11-21 2025-04-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
EP3947383B1 (en) 2019-03-25 2024-10-02 F. Hoffmann-La Roche AG Solid forms of a compound of hbv core protein allosteric modifier
CA3138385A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
US20220227737A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
KR20220002499A (en) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 Novel phenyl and pyridyl ureas active against hepatitis B virus (HBV)
CU20210088A7 (en) 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg COMPOUNDS SUBSTITUTED DERIVATIVES OF INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN112574188B (en) * 2019-09-29 2022-05-06 苏州爱科百发生物医药技术有限公司 Pyrazole compound and application thereof
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2022135601A1 (en) * 2020-12-25 2022-06-30 杭州百新生物医药科技有限公司 5-alkyl-2-pyrazole-oxazolidine-4-ketone derivative and use thereof
CN115677680A (en) * 2021-07-23 2023-02-03 上海挚盟医药科技有限公司 Crystal forms of compound of formula I, preparation and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS [online] CHARY ET AL, accession no. STN Database accession no. 1992:612383 *
INDIAN JOURNAL OF CHEMISTRY, SECTION B; ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 31B, no. 8, 1992 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081627B2 (en) 2014-03-07 2018-09-25 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

Also Published As

Publication number Publication date
WO2006033995A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2003093290A8 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2004028481A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2007084413A3 (en) Methods for treating hepatitis c
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
WO2006130627A3 (en) Methods for treating hepatitis c
EP2361913A8 (en) Anti-infective agents
AU2003249977A1 (en) Imidazole compounds for the treatment of hepatitis c virus infections
ATE490778T1 (en) USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
WO2006075993A3 (en) Nucleoside derivatives for treating hepatitis c virus infection
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2007084435A8 (en) Methods for treating hepatitis c
WO2001045712A8 (en) Combinations of medicaments for treating viral diseases
ATE555794T1 (en) REMEDIES FOR HEPATITIS
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
WO2008100547A3 (en) Compositions comprising lamiridosin, iridoids or derivatives thereof for treatment of hepatitis c or hepatitis b
WO2004078127A3 (en) Continuous delivery methods for treating hepatitis virus infection
WO2003053332A3 (en) Composition and method for treating viral infection
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators
AU2003302275A1 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载